Atogepant reduced the frequency of migraines » Medvestnik


Oral atogepant reduced the average number of migraine days in patients. The most common side effects while taking the drug are constipation and nausea.

Scientists from 16 countries, including Russia, assessed the effectiveness, safety and tolerability of atogepant for the treatment of chronic migraine. The results of the PROGRESS study were published in The Lancet.

Atogepant is an oral CGRP receptor antagonist. During the study, scientists tested two doses of the drug.

The average number of migraine days participants experienced was reduced by 7.5 days in the atogepant 30 mg twice daily group and by 6.9 days in the atogepant 60 mg once daily group. In the placebo group the reduction was 5.1 days. Compared with placebo, the number of migraine days was reduced by 2.4 days in the atogepant 30 mg twice daily group and by 1.8 days in the atogepant 60 mg once daily group.

The most common side effects when taking atogepant are constipation and nausea. The scientists noted that these phenomena were also recorded among participants who received a placebo. In addition, clinically significant reductions in body weight were observed in all three groups. But in the atogepant treatment groups, the reduction was 4% greater than in the placebo group.




The study involved 778 adult patients (average age 42 years) with chronic migraine for one year who received treatment at 142 clinical research centers in 16 countries, including Russia. Participants received oral atogepant 30 mg twice daily, atogepant 60 mg once daily, and placebo. Over the course of 12 weeks of treatment, the researchers assessed changes in the average number of days participants experienced migraines.



Source link